Genitourinary Syndrome of Menopause
Conditions
Brief summary
Estrogen deficiency can occur naturally during menopause or as a secondary effect of various treatments for breast or pelvic cancer and can lead to very disabling vulvovaginal symptoms, since it is associated with an anatomical and functional cellular modification of the urogenital sphere. These changes result in urogenital atrophy responsible for vaginal dryness, painful intercourse (dyspareunia), discomfort, itching and burning sensations, dysuria, urgency and incontinence. These symptoms, which significantly affect quality of life, are found in more than 40% of menopausal women and are grouped under the term Genitourinary Syndrome of Menopause (GSM). General or local estrogen-based treatments improve patients' symptoms, but remain contraindicated in women who have had breast cancer. Non-estrogenic local treatments are less effective, remain restrictive and are therefore often abandoned. The CO2 laser is currently part of the therapeutic arsenal for the management of patients with GSM. This device prevents and eliminates the effects of low estrogen levels on vaginal tissue by restoring the characteristic conditions of the vaginal mucosa of a woman of childbearing age. This simple treatment, which lasts only a few minutes, is safe and painless and has no serious side effects. It restores the tone and elasticity of the tissues, with positive effects on the quality of life and the couple's relationship. The investigators wish to evaluate the possible changes of the genital sphere in a longitudinal way (before, during and after the treatment), including the induced cytohistological changes, in patients with GSM who can benefit of this therapy.
Interventions
DEVICECO2 laser MonaLisa Touch ®
3 sessions of SmartXide fractional CO2 laser via the MonaLisa Touch® device, spaced 4 weeks apart, will be performed. An additional comfort session will be performed at 1 year if needed. The handpiece of the MonaLisa Touch® device is applied to the vaginal walls with a 360° scan, between 800 and 1100µs, to the vaginal orifice
Sponsors
Hopital Nord Franche-Comte
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Women over 40 years of age * Patients with natural menopause or menopause secondary to cancer treatment (breast, pelvis or other) * Patients with vaginal and/or urinary, non-vulvar GSM * Patients for whom CO2 laser therapy is proposed
Exclusion criteria
* Vulvovaginal infections (vaginosis) * Uninvestigated vaginal hemorrhage * Herpes * Pregnancy or breastfeeding * Cervico-vaginal pathology (cervical and/or vaginal dysplasia) * Suspected or diagnosed HPV * Significant vaginal prolapse * Patients on hormone replacement therapy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The main objective of the study is to analyze the evolution of GSM by the use of the MonaLisa Touch ® fractionated laser. | 3 months | The primary endpoint is the comparison of the patient's clinical score composed of a visual analogic scale measuring the intensity of symptoms related to vaginal atrophy (i.e., vaginal burning, vaginal pruritus, vaginal dryness, dyspareunia, and dysuria), before and after 3 laser sessions. |
Countries
France
Outcome results
None listed